Antisense technology is beginning to deliver on the broad promise of the technology. Ten RNA-targeted drugs including eight single-strand antisense drugs (ASOs) and two double-strand ASOs (siRNAs) have now been approved for commercial use, and the ASOs in phase 2/3 trials are innovative, delivered by multiple routes of administration and focused on both rare and common diseases.
What is the function of ribosomes (also known as ribosomal RNA) in protein synthesis? A. Allow interpretation of the two strands of DNA to determine which is the "sense" strand and which is the "antisense" strand B. Serve as the coordinator mechanism to allow proper reading of the mRNA and placement of the correct amino acid in the sequence by the tRNAs C. Allow further processing ofproducts of the sense DNA strands. Just as the sense and antisense DNA strands are complementary, so too are the sense RNA primers and the antisense inhibitor molecules. Con sequently, the sense RNA and the an tisense RNA can hybridize with one another. In this duplexed state, the RNA primer cannot initiate DNA rep lication, because itFurthermore, dual-strand assays showed a 2-fold increase in the number of methylated DNA copies detected when applied to DNA purified from tumor tissue and plasma from CRC patients. When the results of the 3 DNA methylation markers were combined into a ctDNA detection test and applied to plasma, the dual-strand assay format detected 86% of the a. Antisense RNA binds to form double-stranded regions on RNA to either block translation or intron splicing. b. Antisense RNA is transcribed using the sense strand of DNA as a template. c. The sequence of antisense RNA is complementary to mRNA. d. Antisense RNA is made naturally in cells and also artificially in the laboratory. e. Antisense therapy means the selective, sequence-specific inhibition of gene expression by single-stranded DNA oligonucleotides. In contrast, RNA interference (RNAi) is triggered by double-stranded RNA (dsRNA) and causes sequence-specific mRNA degradation of single-stranded target RNAs in response to dsRNA. KbxB. 237 165 454 362 279 363 225 298 98